Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 13 | 2022 | 1026 | 0.740 |
Why?
|
| Pseudomonas Infections | 3 | 2020 | 83 | 0.570 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2020 | 133 | 0.560 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 156 | 0.500 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.480 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2014 | 40 | 0.470 |
Why?
|
| Carrier State | 1 | 2014 | 39 | 0.460 |
Why?
|
| Staphylococcus aureus | 2 | 2014 | 175 | 0.460 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 68 | 0.450 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2013 | 13 | 0.450 |
Why?
|
| Virus Diseases | 1 | 2013 | 31 | 0.450 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 70 | 0.440 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2020 | 226 | 0.430 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 91 | 0.420 |
Why?
|
| Bacteremia | 5 | 2016 | 155 | 0.420 |
Why?
|
| Colony Count, Microbial | 5 | 2015 | 77 | 0.410 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2013 | 98 | 0.360 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 283 | 0.340 |
Why?
|
| Disinfection | 4 | 2013 | 112 | 0.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 3 | 2022 | 37 | 0.300 |
Why?
|
| Copper | 3 | 2013 | 149 | 0.280 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 65 | 0.270 |
Why?
|
| Bacteria | 6 | 2015 | 193 | 0.270 |
Why?
|
| Endoscopes | 2 | 2015 | 36 | 0.250 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2020 | 35 | 0.250 |
Why?
|
| Equipment Contamination | 2 | 2015 | 38 | 0.250 |
Why?
|
| Mycobacterium Infections | 2 | 2016 | 13 | 0.230 |
Why?
|
| Blood Culture | 2 | 2022 | 15 | 0.230 |
Why?
|
| Beds | 2 | 2013 | 13 | 0.210 |
Why?
|
| Bacterial Load | 2 | 2013 | 24 | 0.210 |
Why?
|
| Environmental Microbiology | 2 | 2012 | 25 | 0.200 |
Why?
|
| Pneumonia | 1 | 2022 | 110 | 0.200 |
Why?
|
| Disinfectants | 2 | 2013 | 61 | 0.200 |
Why?
|
| Humans | 34 | 2022 | 68618 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2022 | 175 | 0.190 |
Why?
|
| Fungi | 3 | 2020 | 27 | 0.180 |
Why?
|
| Endocarditis, Bacterial | 2 | 2010 | 32 | 0.180 |
Why?
|
| Microfluidics | 1 | 2020 | 22 | 0.180 |
Why?
|
| Propionibacterium acnes | 1 | 2020 | 10 | 0.180 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2019 | 11 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2019 | 12 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2019 | 35 | 0.170 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2017 | 47 | 0.170 |
Why?
|
| Vancomycin Resistance | 2 | 2009 | 18 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 209 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2009 | 92 | 0.160 |
Why?
|
| Anti-Infective Agents | 3 | 2015 | 166 | 0.160 |
Why?
|
| Orthopedic Procedures | 1 | 2020 | 102 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 168 | 0.160 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 3 | 0.150 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2017 | 9 | 0.150 |
Why?
|
| beta-Lactamases | 1 | 2017 | 33 | 0.150 |
Why?
|
| Cephalosporins | 1 | 2017 | 59 | 0.150 |
Why?
|
| Mycetoma | 2 | 2010 | 3 | 0.140 |
Why?
|
| Mycobacterium chelonae | 3 | 2016 | 9 | 0.140 |
Why?
|
| Actinomyces | 1 | 2016 | 3 | 0.140 |
Why?
|
| Actinomycosis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Pasteurella Infections | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pasteurella multocida | 1 | 2015 | 6 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 245 | 0.130 |
Why?
|
| Fungemia | 1 | 2015 | 13 | 0.130 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 11 | 0.130 |
Why?
|
| Bites and Stings | 1 | 2015 | 34 | 0.130 |
Why?
|
| Coinfection | 1 | 2015 | 30 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2022 | 7277 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 46 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2014 | 111 | 0.120 |
Why?
|
| Placebos | 1 | 2014 | 195 | 0.120 |
Why?
|
| DNA Probes | 1 | 1993 | 57 | 0.120 |
Why?
|
| Streptococcus pyogenes | 1 | 1993 | 20 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2013 | 344 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2019 | 285 | 0.110 |
Why?
|
| Aged | 10 | 2017 | 14862 | 0.110 |
Why?
|
| Enterococcus | 2 | 2014 | 29 | 0.110 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 35 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 62 | 0.110 |
Why?
|
| Legionella | 1 | 2012 | 9 | 0.110 |
Why?
|
| Legionnaires' Disease | 1 | 2012 | 11 | 0.110 |
Why?
|
| Transplantation | 1 | 2012 | 23 | 0.110 |
Why?
|
| Biota | 1 | 2012 | 3 | 0.100 |
Why?
|
| Air Conditioning | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vancomycin | 2 | 2009 | 60 | 0.100 |
Why?
|
| Mycobacterium | 1 | 2011 | 12 | 0.100 |
Why?
|
| Peritonitis | 1 | 2011 | 46 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 30 | 0.100 |
Why?
|
| Health Personnel | 1 | 2014 | 286 | 0.100 |
Why?
|
| Pseudallescheria | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 6 | 0.090 |
Why?
|
| Middle Aged | 9 | 2016 | 21147 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 43 | 0.090 |
Why?
|
| Hemoptysis | 1 | 2010 | 28 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2012 | 163 | 0.090 |
Why?
|
| Female | 14 | 2016 | 38074 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1738 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2010 | 77 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2010 | 108 | 0.090 |
Why?
|
| Adult | 6 | 2022 | 21403 | 0.090 |
Why?
|
| Daptomycin | 1 | 2009 | 11 | 0.090 |
Why?
|
| Male | 10 | 2019 | 37321 | 0.080 |
Why?
|
| Young Adult | 3 | 2016 | 5717 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 178 | 0.080 |
Why?
|
| Sterilization | 3 | 2000 | 29 | 0.080 |
Why?
|
| Adolescent | 3 | 2016 | 8912 | 0.070 |
Why?
|
| Bacteriuria | 1 | 2006 | 7 | 0.070 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2006 | 15 | 0.070 |
Why?
|
| Sickle Cell Trait | 1 | 2006 | 24 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 3 | 2012 | 23 | 0.070 |
Why?
|
| Talc | 2 | 1996 | 3 | 0.070 |
Why?
|
| Clarithromycin | 2 | 2003 | 11 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 92 | 0.060 |
Why?
|
| Glucosides | 1 | 2005 | 16 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 109 | 0.060 |
Why?
|
| Saliva | 1 | 2005 | 142 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2014 | 7029 | 0.060 |
Why?
|
| Corneal Ulcer | 1 | 2003 | 10 | 0.060 |
Why?
|
| Eye Infections, Bacterial | 1 | 2003 | 15 | 0.060 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2003 | 35 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 22 | 0.050 |
Why?
|
| Child | 3 | 2022 | 6405 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2022 | 6 | 0.050 |
Why?
|
| Scedosporium | 1 | 2001 | 2 | 0.050 |
Why?
|
| Keratitis | 1 | 2001 | 20 | 0.050 |
Why?
|
| Uveitis | 1 | 2001 | 13 | 0.050 |
Why?
|
| Contact Lenses | 1 | 2001 | 14 | 0.050 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2001 | 17 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 2891 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 1619 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2022 | 382 | 0.050 |
Why?
|
| Eyelids | 1 | 2000 | 11 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2000 | 12 | 0.050 |
Why?
|
| Retinopathy of Prematurity | 1 | 2000 | 34 | 0.040 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2000 | 32 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 281 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 144 | 0.040 |
Why?
|
| Hospitals | 2 | 2012 | 265 | 0.040 |
Why?
|
| Risk Factors | 3 | 2016 | 5731 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 51 | 0.040 |
Why?
|
| Time Factors | 3 | 2015 | 4655 | 0.040 |
Why?
|
| South Carolina | 2 | 2016 | 2752 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1426 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 492 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2017 | 7 | 0.040 |
Why?
|
| Wound Infection | 1 | 2017 | 20 | 0.040 |
Why?
|
| Immunocompromised Host | 2 | 2010 | 55 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 384 | 0.030 |
Why?
|
| Mycobacterium fortuitum | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 2358 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2015 | 19 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 123 | 0.030 |
Why?
|
| Pleurodesis | 1 | 1995 | 11 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2003 | 1615 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 3705 | 0.030 |
Why?
|
| Cats | 1 | 2015 | 292 | 0.030 |
Why?
|
| Streptococcus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Candida | 1 | 2014 | 15 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 627 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2016 | 110 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 490 | 0.030 |
Why?
|
| Cost Savings | 1 | 2014 | 110 | 0.030 |
Why?
|
| Pharynx | 1 | 1993 | 89 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7367 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2012 | 59 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 85 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 11 | 0.030 |
Why?
|
| Aluminum | 1 | 2012 | 21 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 150 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.030 |
Why?
|
| Cross Infection | 1 | 2013 | 195 | 0.020 |
Why?
|
| Voriconazole | 1 | 2010 | 11 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 281 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2010 | 174 | 0.020 |
Why?
|
| Global Health | 1 | 2009 | 136 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3187 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 197 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 365 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 786 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4848 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 947 | 0.020 |
Why?
|
| Cystitis | 1 | 2006 | 18 | 0.020 |
Why?
|
| Pyelonephritis | 1 | 2006 | 17 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 179 | 0.020 |
Why?
|
| Flavanones | 1 | 2005 | 6 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 1046 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2005 | 144 | 0.020 |
Why?
|
| Isoflavones | 1 | 2005 | 31 | 0.020 |
Why?
|
| Acute Disease | 1 | 2006 | 658 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1553 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 541 | 0.010 |
Why?
|
| Amikacin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 19 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 63 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2003 | 30 | 0.010 |
Why?
|
| Tobramycin | 1 | 2003 | 38 | 0.010 |
Why?
|
| Myopia | 1 | 2003 | 27 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 49 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2003 | 144 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 839 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2005 | 206 | 0.010 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2001 | 3 | 0.010 |
Why?
|
| Peptidyl Transferases | 1 | 2001 | 5 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 1603 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 2007 | 0.010 |
Why?
|
| Point Mutation | 1 | 2001 | 97 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 649 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 223 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 12 | 0.010 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 10 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 2334 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2000 | 44 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1851 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 629 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 20881 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1070 | 0.010 |
Why?
|
| Ethylene Oxide | 1 | 1995 | 3 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1995 | 64 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1995 | 152 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 2455 | 0.010 |
Why?
|